References
- Sharma A, Reddy P, Kuppermann BD, et al. Biosimilars in ophthalmology: is there a big change on the horizon? OPTH. 2018;12:2137–2143.
- Sharma A, Kumar N, Parachuri N, et al. Biosimilars for retinal diseases: an update. Am J Ophthalmol. 2021;224:36–42.
- Sharma A, Kumar N, Kuppermann BD, et al. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br J Ophthalmol. 2020;104(1):2–7.
- Sharma A, Kondo M, Iwahashi C, et al. Approved biosimilar ranibizumab—a global update. Eye [Internet]. 2022 [cited 2022 Sep 29]. Available from: https://www.nature.com/articles/s41433-022-02246-5.
- FDA approves Samsung bioepis and biogen’s BYOOVIZTM (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) | BIOGEN [Internet]. [cited 2022 Sep 29]. Available from: https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11
- FDA Approves Coherus’ CIMERLITM (ranibizumab-eqrn) as the First and Only Interchangeable biosimilar to lucentis® for all five indications, with 12 months of Interchangeability exclusivity | coherus biosciences, Inc. [Internet]. [cited 2022 Sep 29]. Available from: https://investors.coherus.com/news-releases/news-release-details/fda-approves-coherus-cimerlitm-ranibizumab-eqrn-first-and-only/.
- 1st lucentis biosimilar launched in Japan, Senju eyes 6.9 billion yen in 5th year [Internet]. PHARMA JAPAN. [cited 2022 Sep 29]. Available from: https://pj.jiho.jp/article/245767
- » Xbrane provides update on ranibizumab biosimilar candidate FDA filing [Internet]. [cited 2022 Sep 29]. Available from: https://xbrane.com/en/mfn_news/xbrane-provides-update-on-ranibizumab-biosimilar-candidate-fda-filing-2/
- » STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar candidate Ximluci [Internet]. [cited 2022 Sep 29]. Available from: https://xbrane.com/en/mfn_news/stada-and-xbrane-welcome-ema-positive-opinion-for-ranibizumab-biosimilar-candidate-ximluci/
- A study to evaluate CKD-701 and lucentis® in patients with neovascular(Wet) age related macular degeneration - full text view - clinicaltrials.gov [Internet]. [cited 2022 Sep 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT04857177
- Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® (NAP). [cited 2022 Oct 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT04667039
- comparative study to evaluate the efficacy and Safety of MYL-1701P and Eylea® in subjects with diabetic macular edema. [cited 2022 Oct 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03610646
- Mylan Pharmaceuticals Inc. A multi center, extension study to evaluate the safety and efficacy of MYL-1701P in subjects with diabetic macular edema Completed MYL-1701P-3001 Study. [Internet]. clinicaltrials.gov; Report No.: NCT04674800. 2022 [cited 2022 Sep 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT04674800.
- FYB203 [Internet]. Formycon AG. [cited 2022 Sep 29]. Available from: https://www.formycon.com/en/biosimilars/fyb203/
- Biosimilar SB15 indicates equivalent efficacy to aflibercept in nAMD Treatment. [cited 2022 Oct 2]. Available from: https://www.hcplive.com/view/biosimilar-sb15-indicates-equivalent-efficacy-aflibercept-namd.
- [cited 2022 Oct 03]. Available from: https://www.biosimilarsip.com/2022/06/07/purple-book-update-regenerons-eylea-aflibercept/
- [cited 2022 October 2] EU Clinical Trial Register. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-004530-11/HU
- A study to comparing SCD411 and Eylea® in subjects with wet age-related macular degeneration (AMD). cited 2022 Oct 03. Available from: https://clinicaltrials.gov/ct2/show/NCT04480463
- Biosimilars for Retinal Diseases- United States-Europe Awareness Survey (Bio-USER –survey) [ cited 25 Nov 2022]. https://euretina.org/resource/abstract_2022_biosimilars-for-retinal-diseases-united-states-europe-awareness-survey-bio-user-survey/